Elpiscience Partner Compass Report Interim Results of ES104 + Paclitaxel in P-II Study for the Treatment of Biliary Tract Cancers
Shots:
- The P-II study evaluates ES104 + paclitaxel to treat patients with BTC at 4 medical centers in Korea. The company also plans to open additional sites in the US
- The study showed 42% ORR from 10 patients with PRs including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation, CBR (92%) from 22 out of 24 patients with a PR or SD. The therapy was well-tolerated and the preliminary safety profile was consistent with prior studies
- In pre-clinical & early clinical results, the therapy provides robust anti-tumor activity in multiple solid tumors by blocking both DLL4 & VEGF-A signaling pathways. The company has initiated the patient enrolment in the P-I/II study of ES104 to treat mCRC in China
Ref: Businesswire | Image: Elpiscience
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
